AUS
NZ
UK
CA
USA
IND
_06_16_2026_04_54_27_535266.jpg)
Highlights
- AEON Biopharma implements 1-for-72 reverse stock split to maintain NYSE compliance.
- New split ratio approved by stockholders at February 24 meeting.
- Fractional shares rounded up to the nearest whole share post-split.
AEON Biopharma (NYSE:AEON), a clinical-stage biopharmaceutical company, has announced the implementation of a 1-for-72 reverse stock split of its common stock. The reverse split will be effective on February 26, 2025. This decision was approved by the company’s Board of Directors following stockholder authorization at a Special Meeting held on February 24, 2025. During this meeting, stockholders approved a split ratio range between 1-for-5 to 1-for-150.
This reverse stock split aims to increase the price per share of AEON's common stock, thereby helping the company comply with NYSE American’s listing standards, which require that a company’s stock price remain above $1 per share. The adjustment is necessary as the company has been experiencing a decline in stock price, which risked its compliance with NYSE American listing requirements. The company stated that the stock split will not impact the percentage of ownership of its shareholders, except for fractional shares, which will be rounded up to the nearest whole share.
Purpose of the Reverse Split
A reverse stock split is a financial maneuver where a company consolidates its shares to increase the stock price proportionately. In AEON’s case, the reverse split will raise the trading price of its stock to ensure it remains in compliance with the NYSE American's listing rules. The reverse split ratio of 1-for-72 will reduce the number of shares outstanding by a factor of 72, effectively increasing the price per share by the same factor. However, it is important to note that the total value of the shareholder’s holdings will remain unchanged, except for fractional shares, which will be rounded up.
The company will continue trading under its current ticker symbol 'AEON,' but with a new CUSIP number (00791X 209), reflecting the changes following the reverse stock split. The move is a strategic effort by AEON to avoid the risk of being delisted from the NYSE American, which could affect its visibility in the market and limit its access to capital.
In conclusion, AEON Biopharma’s decision to undertake a 1-for-72 reverse stock split is an important move to retain compliance with NYSE American listing standards. While this strategy offers benefits such as maintaining listing eligibility and preserving ownership percentages, it also carries potential drawbacks, including the perception of stock price weakness and the risk of reduced liquidity. The company's ability to overcome these challenges will depend on its ongoing business performance and ability to meet market expectations in the coming months.
